Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced top-line results of the Phase 2 EMBARK study evaluating LIVMARLI® (maralixibat) oral solution versus placebo given as an adjuvant therapy to Kasai surgery in patients with biliary atresia.
- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced top-line results of the Phase 2 EMBARK study evaluating LIVMARLI® (maralixibat) oral solution versus placebo given as an adjuvant therapy to Kasai surgery in patients with biliary atresia.
- The study did not meet its primary endpoint of mean change in bilirubin from baseline to Week 26, or the key secondary endpoints.
- “We are disappointed in the outcome of the study in this post-surgery, high-need disease setting,” said Chris Peetz, president and chief executive officer at Mirum.
- “We are grateful to the patients, families, and clinicians who participated in the study and advanced the science around this rare liver disease.”